United Community Bank Grows Stock Position in Johnson & Johnson (NYSE:JNJ)

United Community Bank increased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 2.5% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 19,492 shares of the company’s stock after buying an additional 469 shares during the quarter. Johnson & Johnson comprises 1.1% of United Community Bank’s holdings, making the stock its 15th largest position. United Community Bank’s holdings in Johnson & Johnson were worth $2,819,000 as of its most recent filing with the SEC.

Other institutional investors have also recently added to or reduced their stakes in the company. IFS Advisors LLC lifted its position in Johnson & Johnson by 138.9% during the fourth quarter. IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after buying an additional 100 shares in the last quarter. RPg Family Wealth Advisory LLC purchased a new position in Johnson & Johnson during the third quarter worth approximately $35,000. Bay Harbor Wealth Management LLC purchased a new position in Johnson & Johnson during the fourth quarter worth approximately $32,000. Activest Wealth Management purchased a new position in Johnson & Johnson during the third quarter worth approximately $40,000. Finally, NewSquare Capital LLC lifted its position in Johnson & Johnson by 145.8% during the fourth quarter. NewSquare Capital LLC now owns 290 shares of the company’s stock worth $42,000 after buying an additional 172 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, Director Mark A. Weinberger acquired 1,000 shares of the stock in a transaction dated Thursday, December 12th. The stock was acquired at an average cost of $147.22 per share, with a total value of $147,220.00. Following the transaction, the director now owns 1,000 shares in the company, valued at $147,220. The trade was a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Robert J. Decker sold 6,999 shares of the business’s stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the sale, the vice president now directly owns 21,001 shares of the company’s stock, valued at $3,483,645.88. The trade was a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Up 0.6 %

JNJ opened at $166.81 on Friday. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99. The stock has a market capitalization of $401.61 billion, a price-to-earnings ratio of 25.08, a PEG ratio of 2.56 and a beta of 0.47. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The business has a fifty day moving average price of $152.95 and a 200 day moving average price of $156.28.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.99 by $0.05. The firm had revenue of $22.52 billion during the quarter, compared to analysts’ expectations of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. Johnson & Johnson’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same period in the previous year, the firm posted $2.29 EPS. Sell-side analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th were given a dividend of $1.24 per share. The ex-dividend date of this dividend was Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 2.97%. Johnson & Johnson’s dividend payout ratio is currently 74.59%.

Analyst Ratings Changes

A number of equities research analysts have commented on JNJ shares. Morgan Stanley reduced their target price on Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 23rd. Guggenheim lifted their target price on Johnson & Johnson from $162.00 to $166.00 and gave the company a “neutral” rating in a research report on Monday, February 3rd. Raymond James reduced their target price on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a research report on Thursday, January 23rd. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 25th. Finally, Argus upgraded Johnson & Johnson to a “strong-buy” rating in a report on Friday, January 24th. Nine investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average target price of $171.33.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.